

# **Currently Available Clinical Trials at Norris Cotton Cancer Center – Kingsbury Pavilion**

## **Brain Cancers**

**None available at this time**

## **Breast Cancer**

**NSABP B-43: “A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy”**

**RTOG 1005: “A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer”**

**SWOG 1007: “A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less”**

## **Gastrointestinal Cancer**

**None available at this time**

## **Genitourinary Cancer**

**RTOG 0524: “A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-**

## **Cystectomy Candidates with Muscle-Invasive Bladder Cancer”**

**RTOG 0534: “Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SUPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy”**

**RTOG 0815: “A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer”**

**RTOG 0926: “A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Re-Staging”**

## **Head and Neck Cancer**

**RTOG 0436: “A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery”**

**RTOG 0920: “A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer”**

## **Hematopoietic Cancer**

**ECOG 2905: “Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia”**

## **Lung Cancer**

**ECOG 1505: “A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB – IIIA Non-Small Cell Lung Cancer (NSCLC)”**

**Symptom Management/Cancer Prevention**

**RTOG 0433: “A Phase III International Randomized Trial of Single Versus Multiple Fractions for Re-Irradiation of Painful Bone Metastases”**

**For more information about these trials, please speak with your oncologist or specialist. Or you may contact the Clinical Research Manager, Erin Lynch, at (603) 354-5454 ext. 2191 ([elynch@cheshire-med.com](mailto:elynch@cheshire-med.com)).**